一免费参会，扫码报名一今日（10月31日），诺和诺德向美国创新型肥胖治疗研发公司Metsera发起主动收购要约，试图“截胡”其与竞争对手辉瑞的既定收购协议。诺和诺德的报价高达每股56.50 美元现金外加每股21.25 美元的或有价值权（CVRs），总价最高可达90 亿美元，明显高于辉瑞此前提出的方案。报价对比：诺和诺德以 90 亿美元挑战辉瑞 73 亿美元方案诺和诺德此次的报价结构中，预付款对应...
Source Link一免费参会，扫码报名一今日（10月31日），诺和诺德向美国创新型肥胖治疗研发公司Metsera发起主动收购要约，试图“截胡”其与竞争对手辉瑞的既定收购协议。诺和诺德的报价高达每股56.50 美元现金外加每股21.25 美元的或有价值权（CVRs），总价最高可达90 亿美元，明显高于辉瑞此前提出的方案。报价对比：诺和诺德以 90 亿美元挑战辉瑞 73 亿美元方案诺和诺德此次的报价结构中，预付款对应...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.